Informations générales (source: ClinicalTrials.gov)
Evaluating the Link Between Active Neovascularization Found on OCT and Eye Fixation Quality Measured With Microperimetry in ARMD Patients Treated With antiVEGF (CORFI)
Observational
University Hospital, Limoges (Voir sur ClinicalTrials)
février 2018
février 2021
29 juin 2024
ARMD is the main cause of visual disability after 50 years old in France. Patients with
active neovascular ARMD are treated with intravitreal injections of antiVEGF.
Reinjections criteria are decrease of best corrected visual acuity or active
neovascularization's signs (mostly found on macular OCT but also on angiography when
necessary).
The aim of this study is to evaluate the link between active neovascularization found on
OCT and eye fixation quality measured with microperimetry in ARMD patients treated with
antiVEGF.
Quality of eye fixation and exudative signs presents or not present on OCT will be
gathered at each consultation over the two-years follow-up for each patient. The mean
central retinal sensitivity, the best corrected visual acuity and the bivariate contour
ellipse area will also be gathered.
In case no link will be found, for instance bad fixation quality without exudative signs
on OCT or good fixation stability despite exudative signs on OCT, microperimetry should
have an interest to improve reinjections criteria with a treatment more suitable to the
patient.
Etablissements
Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
---|---|---|---|---|---|
University Hospital - 87042 - Limoges - France | NATHALIE LABROUSSE, Dr | Contact (sur clinicalTrials) |
Critères
Tous
Inclusion Criteria:
- patients > 50 years old,
- With neovascular ARMD
- who need an induction treatment (de novo patients or patients who had their last
intravitreal injection of antiVEGF more than 6 months ago)
- patients > 50 years old,
- With neovascular ARMD
- who need an induction treatment (de novo patients or patients who had their last
intravitreal injection of antiVEGF more than 6 months ago)
- Other maculopathies
- Severe glaucoma with central visual field defect
- Diabetic patients
- Corneal, lens or vitreous opacities interfering in OCT analysis
- Attention or comprehension deficit